Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Drugs Made In America Acquisition Corp. ( (DMAA) ) is now available.
On April 27, 2026, Drugs Made in America Acquisition Corp. shareholders approved a special resolution to extend the deadline to complete a business combination by up to 12 one-month increments, moving the potential termination date from April 29, 2026 to as late as April 29, 2027, contingent on monthly sponsor contributions to the trust account. The vote, which drew a quorum with about 70.6% of outstanding shares represented and passed with 18,906,281 votes in favor and 4,892,646 against, also triggered redemptions of 9,440,230 shares for roughly $99.3 million, leaving 24,276,913 shares outstanding and narrowing the SPAC’s capital base as its board approved an initial extension to May 29, 2026.
More about Drugs Made In America Acquisition Corp.
Drugs Made in America Acquisition Corp. is a special purpose acquisition company focused on completing a business combination within a defined timeframe using capital raised in its initial public offering. The company maintains investor funds in a trust account until a suitable target is identified and a merger or similar transaction is consummated.
Average Trading Volume: 194,338
Technical Sentiment Signal: Strong Buy
Current Market Cap: $355M
For a thorough assessment of DMAA stock, go to TipRanks’ Stock Analysis page.